Canyon Labs Acquires iuvo BioScience’s Lab Services and Consulting Divisions

Canyon Labs, a leader in analytical and packaging lab testing and consulting for medical devices and pharmaceuticals, has acquired the laboratory services and scientific consulting divisions of iuvo BioScience, a company specializing in ophthalmic medical device and pharmaceutical clinical research services.

While the financial details of the deal have not been disclosed, this acquisition marks a pivotal step for both organizations.

Strategic Impact of the Acquisition

Canyon Labs highlighted in its news release that the acquisition enhances its ability to deliver end-to-end solutions for pharmaceutical and medical device development. Concurrently, iuvo BioScience will focus exclusively on its ophthalmic clinical development contract research services.

Canyon Labs’ Perspective

Sarah (Rosenblum) Ptach, President of Canyon Labs, emphasized the significance of the transaction:

“This acquisition marks a significant milestone in the growth of Canyon Labs' capacity and capabilities. By strategically aligning our organizations, we are delivering immediate value to our global client base through faster lead times, expanded capacities, and unparalleled expertise at every step of the process. This integration strengthens our commitment to raising the standard of service in outsourced testing and consulting for the healthcare industry.”

iuvo BioScience’s Focus

Ben Burton, President and CEO of iuvo BioScience, described the strategic benefits for iuvo:

“This transaction marks a defining moment for iuvo. This strategic decision reinforces our fundamental mission of accelerating patient access to breakthrough vision care treatments. By sharpening our focus on our ophthalmic clinical contract research business, we're strengthening our ability to provide the high touch, science-driven solutions our customers and partners have come to expect from iuvo.”

Conclusion

This acquisition enables Canyon Labs to broaden its offerings and deliver enhanced services across the pharmaceutical and medical device development spectrum. Simultaneously, iuvo BioScience's sharpened focus on ophthalmic clinical contract research strengthens its ability to accelerate innovation in vision care. Both companies are poised to drive impactful advancements in their respective domains, setting new standards in healthcare testing and consulting.